Vanguard Group Inc. Acquires 755,045 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Vanguard Group Inc. increased its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 24.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,803,227 shares of the company's stock after buying an additional 755,045 shares during the period. Vanguard Group Inc. owned about 5.57% of EyePoint Pharmaceuticals worth $28,334,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Franklin Resources Inc. raised its stake in shares of EyePoint Pharmaceuticals by 9.9% in the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock worth $32,056,000 after purchasing an additional 362,399 shares during the last quarter. Geode Capital Management LLC raised its position in shares of EyePoint Pharmaceuticals by 16.1% in the third quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company's stock valued at $9,583,000 after buying an additional 166,699 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of EyePoint Pharmaceuticals by 1,171.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock worth $2,970,000 after buying an additional 342,516 shares during the last quarter. Barclays PLC grew its stake in shares of EyePoint Pharmaceuticals by 410.4% in the third quarter. Barclays PLC now owns 245,045 shares of the company's stock valued at $1,959,000 after buying an additional 197,033 shares in the last quarter. Finally, abrdn plc acquired a new stake in EyePoint Pharmaceuticals in the 4th quarter valued at about $1,719,000. Hedge funds and other institutional investors own 99.41% of the company's stock.

EyePoint Pharmaceuticals Trading Up 2.3 %

Shares of NASDAQ EYPT traded up $0.13 during midday trading on Friday, hitting $5.68. 557,917 shares of the company's stock were exchanged, compared to its average volume of 912,076. The business's fifty day moving average price is $5.94 and its two-hundred day moving average price is $7.84. EyePoint Pharmaceuticals, Inc. has a 12-month low of $3.91 and a 12-month high of $21.26. The company has a market cap of $390.38 million, a price-to-earnings ratio of -2.84 and a beta of 1.39.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The firm had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million. Equities analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating and a $33.00 target price for the company. Chardan Capital reiterated a "buy" rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Finally, HC Wainwright restated a "buy" rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.